Few medical practitoners know that high doses of vitamin B12 can prevent and even reverse the symptoms of Alzheimer's disease and other mental illnesses, but new Codex regulations will restrict access to such high-dosage vitamin therapy.
by Joseph G. Hattersley, MA © 2007
AT-HOME PREVENTION AND REVERSAL OF ALZHEIMER'S DEMENTIA AND SIX OTHER MENTAL ILLNESSES
It is interesting to consider what proportion of Alzheimer's dementia (AD) may result from under-nutrition,1 especially when it seems that an easy, low-cost, perfectly safe nutritional way exists that may allow people to avoid that misery of miseries which many consider worse than death. Some people might say, "That's too good to be true!" However, an at-home nutritional program using a high dosage of vitamin B12 may prevent and virtually eliminate AD. An early launch of the treatment soon after first warning symptoms start could even turn off the process.
Confusion, difficulty concentrating, loss of memory, marked changes in personality that can lead to outbursts of violence, hallucinations, wandering away and early death all characterize Alzheimer's dementia.
An estimated 2.3 million Americans now have AD. Prevalence doubles every five years after the age of 60, increasing from one per cent among those 60 to 64 years old up to 40 per cent of those aged 85 years and older.
Nursing home care costs about US$47,000 per AD patient annually and this figure is rising steadily, putting a huge burden on the health care system. The disease is also terrible for the patients' caregivers. In what experts are calling "a looming public health disaster", statistics suggest there will be between five and seven million Alzheimer's patients in the USA over the next 10 years.2
Let's start with a little background. Mammals, including humans, are born with serum levels of vitamin B12 at about 2,000 pg/mL (picograms, i.e., trillionths of a gram, per millilitre). The level declines throughout human life owing to practices common in Western societies.4 Below 550 to 600 pg/mL, deficiencies start to appear in the cerebrospinal fluid.5, 6 US clinical laboratories regard 200 pg/mL as the lower range of normal. That low limit was set with haematologic criteria. But neuropsychiatric criteria, which are much higher, have become more critical.
"Most cases of Alzheimer's dementia are actually missed B12 deficiency cases, because of the too-low normal range for B12," wrote John V. Dommisse, MD, in 1991 in Medical Hypotheses.3 Dommisse, who practises medicine in Tucson, Arizona, has confirmed that Alzheimer's disease appears to result from too-low serum vitamin B12, and repletion of the vitamin succeeds despite other risk factors.7, 8, 9 Replenishing B12, according to Dommisse, can reverse 75 per cent of B12 deficiency dementias when discovered early enough.10
As mentioned above, B12 therapy is perfectly safe; in other words, the risk of overdose is virtually nil. Here's the proof... Patients of Dr H. L. Newbold in New York City injected themselves three times daily with triple-strength doses of B12 (9,000 micrograms/day as hydroxycobalamin, the natural form) indefinitely. Their serum B12 levels reached 200,000 pg/mL (100 times the normal level found in newborn babies and higher). But none had any significant side effects.3
Other aspects of the therapy should be noted: The neurological and cerebral manifestations of B12 deficiency require dosages larger,11 and extending over a longer time,12 than those needed to reverse haematologic effects;13 and there is no reason to run the risk of not catching deficiency in time or to go to any unnecessary expense and inconvenience. To put it bluntly: try the harmless therapy and see if you, the patient, benefit(s).
Other Conditions Benefit From B12 Replenishment
Besides Alzheimer's disease, B12 ("cobalamin"*) deficiency can also cause the following conditions. And when started early, replenishing B12 (i.e., restoring it to or near to levels found at birth) may often significantly improve these afflictions as well:
* Depression. Often in mild form, depression can be one of the first clues foretelling dementia.14-19 Chris Reading, BSc, DipAgSc, MBBS, of Australia concurs: "... in most cases of [not only mild but also] 'intractable depression', a subtle B12, or other nutrient, or thyroid hormone, deficiency has been missed."20, 21 Psychotic depression has been particularly associated with B12 deficiency.22
As I'll discuss later, success of B12 therapy against depression in its various forms is "probable".
* Paranoid psychosis. This nutritional deficit has also been linked to paranoid psychosis, characterised by over-suspiciousness and delusions of grandeur or persecution.23
* Bipolar-1 disorder (manic depression), marked by alternating periods of elation and depression; and more commonly bipolar-2 disorder (cyclothymic personality), marked by swings of mood but within normal limits.24, 25, 26
* Chronic fatigue syndrome.27, 28, 29
* Weakened immunity. Weakened immunity can lead to susceptibility to recurrent infections and cancer, as well as increasing the risk of cardiovascular disease, cancer30 and much more by a second pathway: hindering remethylation of the toxic sulphur amino acid homocysteine back into the nontoxic essential amino acid methionine.31
* Asthma. Incomplete digestion of foods due to hypochlorhydria and low pepsin production (see below) can be involved in a subsequent allergic response in asthma.32
* Disrupted sleeping/waking rhythms.33, 34
* Environmental illness.35
* Low stress tolerance.36
* AIDS (acquired immuno-deficiency syndrome).38
* Premature ageing.39
* Multiple sclerosis.40, 41 Symptoms of MS have been noted in persons with a vitamin B12 deficiency prior to evidence of megaloblastic anaemia. There is a remarkable epidemiologic similarity between MS and pernicious anaemia, and similar HLA (human lymphocyte antigens) are suggested for the association of the two conditions.
* Alzheimer's mimicking and non-Alzheimer's dementia.42
Intramuscular injection of B12 also has yielded seeming miracle cures in still other desperate illnesses. Further, in numerous cases of patients with violent behaviour, when B12 was replenished (with or without other changes in life), violent behaviour disappeared.45-49
"The only question now," writes Dommisse, "is, what proportion of cases of mood-disorder is caused by B12-deficiency and what percentage is idiopathic." Almost all of his uni- and bipolar patients have had B12 levels in the lowest one-third of the so-called normal (to prevent pernicious anaemia) range--levels that he now regards as deficient for adequate affective, cognitive and other mental functions. When their levels have been raised to the highest one-third of that "normal" range, every one of those patients felt better. For some patients who came out of their depression or mood-swing disorder, this was the only new or different treatment they received. In subsequent instances when their affective disorder worsened, B12 levels had again dropped.
So, would restoring ample serum B12 levels prevent many or most of those adverse conditions? Evidence shown below, Dr Dommisse cautiously suggests, means, "Yes, at least in the case of depression".
There is no maximum allowable age to begin B12 therapy. Everyone loves an anecdote. A friend told me her 90-year-old live-in mother was beginning to think less clearly than in the past and to feel a bit depressed. I suggested: "If your dear mother would like to stop her incipient downward slide, let her start the therapy." God never wrote on tablets of stone that 90 years of age is too old to turn one's health around and begin to make life fun again. After a few weeks on high-dose B12 she was out in the woods with her daughter gathering items of interest. But three years later she "felt terrible" for want of enough water (F. Batmanghelidj, MD's authoritative study, Your Body's Many Cries for Water, states that chronic dehydration is the cause of AD).
Having a quality laboratory measure serum B12 is an essential part of the replenishment process. Simply supplementing B12 "in the dark" could miss the mark badly. And to really know the patient's whole picture, Sherry A. Rogers, MD, suggests the ION (Individualised Optimum Nutrition) Panel is well worth its cost (currently, about US$600; in the USA, contact NEEDS on 1800 634 1380).50
The normal range for serum B12, states Dr Dommisse, should be defined as 600 to 2,000 pg/mL. Japan's "normal" range is 500-1,300.51 According to Dommisse, this may explain why Japan has such a low rate of Alzheimer's dementia52 compared to the USA.53 By some estimates, as many as 80 per cent of elderly American patients may share hidden B12 insufficiency.54, 55, 56
Also, B12 deficiency is common with folate deficiency in dementia57, 58, 59 and worsens over time as the deficiency increases.60 The impact was seen first on neuropsychiatric measures; augmentation of B12 and folate materially improved scores on cognitive performance tests.61, 62
(* The name "cobalamin" has been advocated because the large B12 molecule includes a cobalt molecule; see W. S. Beck, "Cobalamin and the nervous system" [editorial], New Eng J Med 1988; 318:1752-54. However, about one-third of this vitamin's molecule is not cobalamin, but metabolically inactive crinoids which may be effective for bacteria but do not serve as haemopoietic agents; see J. S. Bland, Preventive Medicine Update, October 1994. See also Addendum.)
Methods of Treatment
The most direct method for adding these megadoses of B12 is through intramuscular (IM) injection, which requires a doctor's prescription and a doctor's or nurse's instruction. It is about as difficult technically as pushing a pin into a ripe orange63 and can be economical if a patient can self-administer or a companion can administer.
Another feasible approach uses inexpensive sublingual B12 at 2,500-5,000 mcg (2.5 to 5 mg), which anyone can buy at a quality health food store. Taken in that way, evidence indicates that most of the vitamin goes via the lymphatic system (see Sherry A. Rogers, MD, Detoxify or Die, 2005 ed., p. 270). Therefore, this treatment mode may yield more benefit by avoiding the digestive system.65
Causes of B12 Insufficiency
Several common features of modern life accelerate the decline of vitamin B12 in serum through life, including the following:
* Microwave ovens. In one test, microwaving milk degenerated 30-40 per cent of its vitamin B12 content in six minutes; with conventional heating, 25 minutes of boiling was needed to depress B12 that much.67 More importantly, the heat of microwaving destroys all the enzymes in ingested food, which are required to enable absorption and utilisation of food. And so by eating microwaved food, both at home and in restaurant and take-out meals, tens of millions of Americans are making themselves increasingly vulnerable to AD as well as to cancer. One further note: microwaving, invented by the Nazis, is wisely forbidden in Russia.67
* The Western diet. B12 ingestion and stores tend to be insufficient among millions who have for decades eaten RDA-fortified, yet vitamin- and mineral-depleted, processed Western diets, which are also big sources of disease-creating free radicals.69 Too low levels of omega-3 essential fatty acids in Western diets, harmful on their own in many ways, must also contribute to insufficient B12 levels.70 Omega-3 supplementation may yield its benefits largely through augmenting vitamin B12. Too-low levels of acetyl-carnitine and folic acid also appear to worsen the risk of the condition.71, 72
It's worth noting that in an Alzheimer's disease mouse model, a diet rich in omega-3 essential fatty acids, specifically DHA (docosahexaenoic acid), has been shown potentially to slow or even to prevent Alzheimer's disease.73 At modest cost, we can easily ingest DHA and EPA (eicosapentaenoic acid) in fish oil or cod liver oil (I find the Carlson brand to be the best). And how about trans-fatty acids found in products labelled "zero trans-fats" with EPA approval? In a study of over 800 seniors, those with high TFA intake were twice as likely to suffer with Alzheimer's disease as those with the lowest intake (firstname.lastname@example.org, 17 February 2006).
* Hypochlorhydria. Most commonly, B12 insufficiency results directly from hypochlorhydria (insufficient hydrochloric acid [HCl] in the stomach) or by achlorhydria (no HCl at all). The acid should be concentrated enough, in middle age, to dissolve a nail in an hour.77 Hypochlorhydria is likely caused by zinc or vitamin B6 deficiency78 and a shortage of ionised calcium.79, 80 (Both deficiencies are typically present in older people.) Lack of enough pepsin or HCl in the stomach to generate the bond between B12 and its carrier protein typically shows with atrophic gastritis.81, 82 Both are also risk factors for gastric cancer.83 Incomplete digestion of foods due to hypochlorhydria and low pepsin production also can be involved in subsequent allergic response in asthma.84
* Intrinsic Factor, Bacteria, Cobalamid, Failure of Absorption. B12 deficiency can also result from inadequate stomach secretion of the tiny open-ended protein capsule known as "intrinsic factor"; from presence in the gut of bacterial overgrowth;85 from ingestion of cobalamid, a B12 antagonist;86 or failure of absorption for other reasons.87
* Antacids and Antibiotics. Chronic overuse of antacids, both prescribed and over the counter (OTC), by tens of millions of elderly people may also be responsible. When all the acid is mopped up daily by antacids, the B vitamins never even get to first base.88 For example, B12 absorption is dramatically reduced when the drug Prilosec (omeprazole), which has recently been made available OTC in the USA, is used.89, 90 "A significant percentage of patients taking omeprazole are also being treated for or are at high risk of heart disease, and therefore almost all are instructed to eat a diet low in red meat (or devoid of it completely) and of animal products, which are the best source of vitamin B-12".91 Also, omeprazole reduces gastric (stomach) levels of multi-protective ascorbic acid (vitamin C),92 still another route to cancer (see J. G. Hattersley, "Alzheimer's dementia, vitamins B12 and B6, lithium, gingko biloba, dental mercury, genetic risk, and drinking water fluoridation", J Appl Nutr 2005).
This is an egregious example of iatrogenic disease, created by tunnel-visioned one-organ specialists (who seldom if ever communicate with each other) using a "band-aid" approach to treatment of a symptom or test reading, oblivious to the possibly disastrous long-term effect on the patient. Other causes of B12 deficiency include excessive long-term use of antibiotics and other drugs to mask symptoms without learning and correcting their cause; oral antibiotics destroy the trillions of "good" bugs in the gut as well as the bad, thus ruining absorption.93
* Vegan Diets. Many vegan (total) vegetarians have for decades consumed few, if any, foods containing B12. As a result, their body stores of the vitamin have gradually diminished. Forty-seven of 78 adult vegans had levels below 200 pg/mL; when they chewed a 100-microgram B12 tablet once a week, their levels promptly rose to normal.94 Some vegans depend on sea vegetables such as arame, wakame and some varieties of kombu, or on algae.95 The B12 in these, although absorbed, may not be fully bio-available.96 A study published in the May 2003 Townsend Letter for Doctors and Patients (TLfDP) provided strong evidence that a commonly consumed seaweed known as nori does, in fact, contain bio-available forms of B12.97 But whether that substance is available to large numbers of vegans and whether its use would lift serum B12 levels enough is not known. And in a recent study from India published in Neurology India,1 most of the B12-deficient people studied were "vegetarian".
Vitamin B12 Repletion Succeeds Despite Risk Factors
In his study, Dr Dommisse does not reveal, or need to know, the proportion of his patients who experience other AD risks: for example, how many are thyroid deficient, drink fluoridated water, have extensive dental amalgams, take Ibuprofen98 (some non-steroidal anti-inflammatory drugs, along with their famous multitude of adverse effects, may lower AD risk by about 50 per cent99), etc. He doesn't consider the number of patients who have been exposed occupationally to electro-magnetic fields, which promote the formation of beta amyloid, a protein common in the brains of Alzheimer's patients.100, 101 Nor does he present any numbers showing high content of aluminium in AD patients' brains102 from consumption of aluminium-treated drinking water103, 104 and/or from consuming a variety of everyday sources (refer also to the combination of aluminium-containing alum with fluoridated water in J. G. Hattersley, J Appl Nutr 2005). Dommisse's study also doesn't consider the extent of use of melatonin as a brain antioxidant to counteract accumulation of free-radical-creating iron,105 nor does it look at potentially brain-damaging homocysteine in patients' serum.106, 107
[As a side note, possible mechanisms for spinal cord and peripheral nerve effects of vitamin B12 deficiency include axonal degeneration and demyelination of insulating nerve sheaths.108 Deana et al. found low levels of neurotransmitters in the brains of B12-deficient rats.109 A University of Kentucky study found impaired G-protein signalling and proposed a feed-forward cycle of progressive neuronal dysfunction, related to phosphoinositide signalling.110 Spector et al. have hypothesised that idiopathic (Alzheimer's) dementia is a brain-vitamin-deficiency state due to inadequate transport of vitamins from the blood across the choroid plexus (the "blood brain barrier") and into the cerebrospinal fluid--the only source of these nutrients for the brain.111]
Dr Dommisse prefers vitamin B12 as hydroxycobalamin. A person taking cyanocobalamin from a pharmacy might over a long period of years accumulate a toxic amount of cyanide and possibly damage vision.112 (Many patients in Britain using cyanocobalamin from a pharmacy did go blind due to damage to the optic nerve, and few physicians knew of it [letter 9/3/05 from Wayne Martin, TLfDP contributing writer, Fairhope, Alabama]).
Also, methylcobalamin, widely used in Japan, is increasingly popular in the USA, in part because it is reputed to be better absorbed. Certain OTC sublingual preparations provide methylcobalamin, which in the absence of alcoholic and other liver damage is the only version of B12 that penetrates the blood-brain barrier (the choroid plexus) and reaches the brain and spinal cord (Sherry A. Rogers, MD, Detoxify or Die, p. 270).
In Preventive Medicine Update (May 1995), Jeffrey Bland, PhD, reported: "Five clinician/subscribers have sent clinical case histories. On high-dose folate/B12/B6, homocysteine levels dropped... Also, a number of reports have come... about patients suffering with presenile dementia or Alzheimer-like symptoms. On IM B12, their MMA (methyl malonic acid levels, an indication of deficient B12 status) came down to normal range, and their walking, balance, gait, and perception improved. I've had reports of individuals who had not been able to read, start to read, people who had not been able to look at video screens now comfortable looking at them, and two reports of people who had movement dystonia, who after vitamin B12 therapy were able to get in the car and be transported without fear of being unable to accommodate passing scenery. So there is a wide range of very important clinical outcomes from improving folate/B12/B6 status, cutting across neurological and arterial functional status."113
Because the typical environmentally ill (EI) patient often has low zinc, B6 and thyroid hormone levels, low chromium glucose tolerance factor (GTF) and high candida/low bifidus as well as low B12, to suggest B12 alone as the sole treatment would not be consistent with holistic thinking, suggested Dr Earl Conroy.114 So, if high-dose B12 doesn't do the trick pretty fast, consider additional measures, guided by the results of the ION Panel test, if given.115
Little research has been published about B12 therapy for AD and other neurological diseases, Dommisse writes, because of the "...heavy pharmaceutical industry sponsorship of research and teaching in medical schools. Career-track academicians have realised that, if they want to fulfill their ambitions, they have to eschew nutritional research for that of drugs."3 The volume of published research on drugs to fight Alzheimer's disease is overwhelming. To continue their careers, the authors of these studies have a powerful financial incentive to report positive results, whether truthful or not. Yet, the best that Alzheimer's drugs can do is to conceal the symptoms for a while. The underlying cause--notably, deficiency of vitamin B12--continues to worsen unabated.
In that vein, I offer a caution on cholesterol-lowering statin drugs. Ten years ago I exposed these high-margin products, along with others, as potential patient-killers.116 Big Pharma is waking up belatedly to that fact. Now pharmaceutical companies would like to promote statins as preventives for Alzheimer's dementia. Drug therapies reported up to September 2005 showed no success (Acres USA, September 2005).
A recent CBS Evening News report quoted a University of California medical professor who is conducting new government-funded (not drug-maker-funded) research on statin drugs' effect on Alzheimer's-susceptible patients: "We have people who have lost thinking ability so rapidly that within the course of a couple of months they went from being heads of major divisions of companies to not being able to balance a checkbook and being fired from their companies."117, 118
Vitamin B12 therapy still faces a very real obstacle: Codex regulations, likely to go into effect in the near future, will prohibit any dose of any vitamin to be sold at much above the Recommended Dietary Allowance (RDA). For B12, the adult RDA dosage is only 3.02 micrograms. Millions will suffer and die from this terrible B12-preventable disease if that Codex regulation is enforced. And a new bill in Congress, cited in TLfDP (November 2005) by David Musnick, MD, will reinforce Codex restrictions.
One final note. It is important to cultivate a positive, optimistic outlook to maximise the prospect for success against such mental diseases. One should avoid the scenario in which the attending physician tells the cancer patient, "You have x months to live". Classes and groups for Alzheimer's-fearing people often move in that direction. In fact, I have heard of no AD awareness classes that even mention vitamin B12 therapy in a positive way. Physicians, whose medical education omitted or put a negative spin on anything using nutrition, may be behind the structure of many such classes. What a different story it might be if instruction and awareness emphasised the usually successful measures brought out in this article. One has to ask: why don't doctors at least tell the public about this seemingly magical therapy, which is available to all at trivial cost? Just think about that, and the answer becomes obvious. °
About the Author:
Joseph G. Hattersley has an MA in Economics from the University of California-Berkeley. In 1953, he completed all requirements for a PhD except the dissertation. In 1976, at age 54, a seeming nutritional miracle launched his career of writing on a wide range of health topics. Mr Hattersley has previously contributed two articles to NEXUS: "Soybean Products: A Recipe for Disaster", in vol. 4, no. 3, and "The Healing Power of Full-spectrum Light" in vol. 8, no. 4.
Mr Hattersley can be contacted by post at 2209 Craig Road SE, Olympia, WA98501, USA, by telephone on +1 (360) 352 3688 and by email on email@example.com.
1. Bland JS. Funct Med Update 2002; August.
2. Centers for Disease Control. Mortality from Alzheimer's disease - United States 1979-1987. JAMA. 1991; 265(3):313-317.
3. Dommisse JV. Med Hypotheses. 1989.
4. Dommisse JV. Subtle vitamin-B12 deficiency and psychiatry: A largely unnoticed but devastating relationship? Med Hypotheses. 1991; 34:131-140.
5. Regland B. Vitamin-B12 Deficiency in Dementia Disorders (Monograph/doctoral thesis, comprising six papers, with co-authors). Dept. of Psych. and Neurochem, University of Goteborg, Sweden. January 1991.
6. Ikeda T, Furuwaka Y, Mashimoto S et al. Vitamin B12 levels in serum and cerebrospinal fluid of people with Alzheimer's disease. Acta Scand Psychiatrica 1990; 82; 4:327-329.
7. Dommisse JV. Psychiatry and vitamin B12 deficiency. Kirk Hamilton, PAC, Clinical Pearls News. March 1998: Interview.
8. Dommisse JV. Subtle vitamin-B12 deficiency and psychiatry. Op. cit.
9. Spector R, Cancilla P, Damasio AR. Is idiopathic dementia a regional vitamin-deficiency state? Op. cit.
10. Roos D. Neurological complications in patients with impaired vitamin B12 absorption following partial gastrectomy (monograph/D Med Sci thesis). Supplement 69 to Acta Neurologica Scandinavica. 19, Minksgaard, Copenhagen, 1978.
11. Roos D. Neurological complications in patients with impaired vitamin B12 absorption. Idem.
12. Whitehead JA, Chosen MM. Paraphrenia and pernicious anaemia. Geriatrics. 1972; May: 148-158.
13. Smith ADM. Megaloblastic madness. Brit Med Jour. 1960; 2:1840.
14. Ferrara A, Arieti S, English WH. Cerebral changes in the course of pernicious anaemia, and their relationship to psychic symptoms. Jour of Neuropathology & Experimental Neurology. 1945; 4:217.
15. Burvill PW, Jackson JM, Smith WG. Psychiatric symptoms due to vitamin-B12 deficiency without anaemia. Med Jour Australia. 1969; Aug 23:388-390.
16. Levitt AJ, Joffe RT. Vitamin B12 in psychotic depression. Brit Jour Psychiatry. 1988; 153:266-267.
17. Phillips SL, Kahamer KP. An unusual presentation of vitamin-B12 deficiency (letter). Amer Jour Psychiatry. 1983; 145; 4:529.
18. Evans DL, Edelsohn GA, Golden RN. Organic psychosis without anaemia or spinal cord symptoms in patients with vitamin-B12 deficiency. Amer Jour Psychiatry. 1983; 140; 2:218-221.
19. Elsborg L, Hansen T, Rafaelson OJ. Vitamin-B12 concentrations in psychiatric patients. Acta Psychiatrica Scandinavica. 1979; 59:145-152.
20. Reading CM. X-linked dominant manic-depressive illness: Op. cit.
21. Reading CM. Latent pernicious anaemia: A preliminary report. Med Jour Australia. 1975; (Jan. 25) 1:91-94.
22. Levitt AJ, Joffe RT. Vitamin B12 in psychotic depression. Brit Jour Psychiatry. 1988; 153:266-267.
23. Lindenbaum J, Healton EB, Savage DG et al. Neuropsychiatric disorders. Op. cit.
24. Reading CM. Latent pernicious anaemia (letter to the editor). Med Jour Australia. 1975; March 29:430-431.
25. Zucker DK, Livingston RL, Narka R, Clayton P. B12-deficiency and psychiatric disorders: Case-report and literature review. Biological Psychiatry. 1981; 16; 2:197-205.
26. Van Tiggelen CJM, Peperkamp JPC, TerToolen JFW. Assessment of vitamin-B12 status in CSF. Amer Jour Psychiatry. 1984; 141; 1:136-137.
27. Ellis FR, Nasser S. A pilot study of vitamin-B12 in the treatment of tiredness. British Jour Nutrition. 1973; April.
28. Lindenbaum J, Healton EB, Savage DG et al. Neuropsychiatric disorders. Op. cit.
29. Reading CM. X-linked dominant manic-depressive illness: Linkage with Xg blood--group, red-green color-blindness and vitamin-B12 deficiency. Orthomolecular Psychiatry. 1979; 8; 2:68-77.
30. Bland JS. Functional Medicine Update. 2004; Jan.
31. McCully KS. Homocysteine theory. Development and current status. Atherosclerosis Rev. 1983; 11:157-246.
32. Wright JV. Treatment of childhood asthma with parenteral vitamin B12, gastric re-acidification, and attention to food allergy, magnesium and pyridoxine: Three case reports with background and an integrated hypothesis. J Nutr Med. 1990; 1:277-282.
33. Ohta T et al. Treatment of persistent sleep/wake schedule disorders in adolescents and vitamin B12. Jap J Psych Neurol. 1991; 45:167-168.
34. Ohta T et al. Treatment of adolescent patients with sleep-wake schedule disorders who complain of non-attendance at school. Chronobiology: Its role in clinical medicine, General Biology and Agriculture. Part B, Wiley-Liss Inc., 1990: 65-72.
35. Dommisse J. Subtle vitamin-B12 deficiency and psychiatry: A largely unnoticed but devastating relationship? Med Hypotheses. 1991; 34:131-140.
36. Chrouses GP, Gold PW. The concepts of stress and stress system disorders. JAMA 1992; 267:1244-1252.
37. Gaby A. B6. The Natural Healer. New Canaan, CT: Keats Publ, 1987.
38. Shor-Posner G. Plasma cobalamin levels affect information processing speed in a longitudinal study of HIV-1 disease. Arch Neurology. 1995; 52:195-201.
39. Spector R, Cancilla P, Damasio AR. Is idiopathic dementia a regional vitamin-deficiency state? Med Hypotheses. 1979; 5:763-767.
40. Multiple sclerosis. Int Acad Nutr Prev Med. Your Health. 1991; 14(4):1-3.
41. Folate deficiency and cancer. In: Bendich A, Butterworth CE Jr., eds. Micronutrients in Health and in Disease Prevention. NY: Marcel Dekker: 165-183.
42. Hattersley JG. High-dose vitamin B12. Unpublished survey of the literature with a note on ginkgo biloba and amendments by Earl W. Conroy, DC, ND of New Zealand. September 26, 1995 (With update on Alzheimer's disease, July 1999).
43. Thieu L. Nghiem, MD, PhD, Interview 1989.
44. Collin, Jonathan, MD. Lecture tape, 1991.
45. Rimland B. Innovative approaches to criminality, delinquency and violence. Int Jour Biosocial Research. 1981; 2:43-48.
46. Story M, Rosen GM. Diet and adolescent behaviour. Psychiatric Annals. 1987; 17; 12: 811-817.
47. Schoenthaler SJ. Institutional nutritional policies and criminal behaviour. Nutrition Today. 1985; May/June: 16-24.
48. Schauss AG, Simonsen CE. A critical analysis of the diets of chronic juvenile offenders. Jour Orthomolecular Psychiatry. 1979; 8:149-157.
49. Hippchgen JF. Some possible biochemical aspects of criminal behaviour. Int Jour Biosocial Research. 1981; 2:37-42.
50. Rogers SA. Total Wellness. September 2004.
51. Mitsuyama Y, Niegoh H. Serum and cerebrospinal fluid vitamin B12 levels in demented patients with CH3-B12 treatment--Preliminary study. Jap Jour Psych Neurology. 1988; 42; 1:65-71.
52. WHP Scientific Group on Senile Dementia. Dementias in late life: research & action. Technical Report Series 730. Geneva: World Health Organization, 1986.
53. The psychiatric manifestations of B12 deficiency. Primary Psychiatry. 1996; April: 18, 21.
54. Wallace DC. Mitochondrial genetics: A paradigm for aging and degenerative diseases. Science. 1992; 256:728-732.
55. Privitera J. Clots: Life's biggest killer. Lecture, 1993.
56. Carmel R. Subtle and atypical cobalamin deficiency states. Am J Hematol. 1990; 34:108-114.
57. Bland JS. Prev Med Update. 1993; July.
58. Arnold SE, Kumar A. Reversible dementias. Med Clin NA. 1993; 77:215-230.
59. Cunha UGV. An investigation of dementia among elderly outpatients. Acta Psychiatr Scand. 1990; 82:261-263.
60. Crystal HA et al. Serum vitamin B12 levels and incidence of dementia in a healthy elderly population. J Am Geriatr Soc. 1994; 42:933-936.
61. Bland JS. Prev Med Update. 1995; Apr.
62. Pirttila T et al. Effect of advanced brain atrophy and vitamin deficiency on cognitive functions in non-demented subjects. Acta Neurol Scand. 1993; 87:161-166.
63. Jonathan Collin, MD, Recorded lecture 1991.
64. Kuzminski AM, Del Giacco EJ, Allen RH, Stabler SP, Lindenbaum J. Treatment of cobalamin deficiency with oral cobalamin. Ann Pharmacother. 2002; 36:1268-1272.
65. Flanagan, Patrick, MD, PhD. Hydrogen: The missing link in understanding aging. Anti-Aging Medical News. 1999; Winter:19-20.
66. Health Freedom News. Summer 2004,
67. Dr. Fumio Watanabe of Japan's Kochi Women's University. Reported in email "Nuking food - Is your kitchen microwave safe?" From Patty Martin firstname.lastname@example.org., 9/7/2004.
68. Lee Lita, PhD. Microwaves & microwave ovens. 5/14/01.
69. Conroy Earl, DC, ND. Email, 2002.
70. Lord RS, Bralley JA. Polyunsaturated fatty acid-induced antioxidant insufficiency. Integrative Medicine. Dec. 2002/Jan. 2003; 1:138-143.
71. Living better for longer: Can supplements improved aging? A rat study suggests they may. ABC News. Available at www.abcnews.com. Accessed 1/22/04.
72. Dietary supplements make old rats youthful, may help rejuvenate aging humans, according to UC Berkeley Study. Science Daily. Available at www.sciencedaily.com. Accessed 2/19/02.
73. Calon F, Lim GP, Yang F, Morihara T, Teter B et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron. 2004; 43:633-645.
74. Greenfield JG, O'Flynn E. Subacute combined degeneration and pernicious anaemia. Lancet. 1933; 2:62-63.
75. Jewesbury ECO. Subacute combined degeneration of the cord and achlorhydric peripheral neuropathies without anaemia. Lancet. 1954; 2:307-312.
76. Doscherholmen A, Swaim WR. Impaired assimilation of egg Co57 vitamin B12 in patients with hypochlorhydria and achlorhydria and after gastric resection. Gastroenterology. 1973; 4:913-919.
77. Wright JV. Radio broadcast on KVI radio in Seattle, 1993.
78. Earl W. Conroy, ND, DC. Personal communication, 1992.
79. Dunne, Lavonne. Nutrition Almanac, 3rd ed., New York: McGraw- Hill, 1990.
80. Lipski Elizabeth, MS, CCN, Digestive Wellness. Connecticut: Keats Publishing Co., 2000.
81. Dawson DW, Sawers AH, Sharma RK. Malabsorption of protein bound vitamin B12. Br Med J. 1984; 288:675-678.
82. Suter PM, Golner BB, Goldin BR et al. Reversal of protein-bound vitamin B12 malabsorption with antibiotics in atrophic gastritis. Gastroenteritis. 1991; 101:1039-1045.
83. Seery JB. Achlorhydria and gastric carcinogenesis. Lancet. 1991; 338:1508-1509.
84. Wright JV. Treatment of childhood asthma with parenteral vitamin B12, gastric re-acidification, and attention to food allergy, magnesium and pyridoxine: Three case reports with background and an integrated hypothesis. J Nutr Med. 1990; 1:277-282.
85. Nilsson-Ehle H, Landahl S, Lindstedct G et al. Low serum cobalamin levels in a population study of 70- and 75-year-old subjects. Gastrointestinal causes and hematological effects. Dig Dis Sci. 1989; 34:716-723.
86. Bland JS. Prev Med Update. January 1995.
87. Yao Y et al. Decline of serum cobalamin levels with increasing age among geriatric outpatients. Arch Fam Med. 1994; 3:918-922.
88. West B. Brain function and antacids. Health Alert. 1995; 12(4):3- 4.
89. Saltzman JR et al. Effect of hypochlorhydria due to omeprazole treatment of atrophic gastritis on protein-bound vitamin B12 absorption. J Amer Coll Nutr. 1994; 13(6):584-591.
90. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B-12). Ann Intern Med. 1994; 120:311-215.
91. B12 deficiency from drugs. email@example.com 8/18/2004.
92. Mowat C, Carswell A, Wirz A, McColl KE. Omeprazole and dietary nitrate independently affect levels of vitamin C and nitrite in gastric juice. Gastroenterology. 1999; 116:813-822.
93. Rogers SA. Interview on Bland JS, Prev Med Update. July 1992.
94. Crane MG. Vitamin B12 studies in total vegetarians. J Nutr Med. 1994; 4:419-430.
95. Rogers SA. Letter to Bland JS, Prev Med Update. April 1995.
96. Am J Clin Nutr. 1991; 53:695.
97. Gaby AR. Vegetarian source of vitamin B12 (Literature review & commentary brief article). TLfDP. May 2003:32.
98. Wyss-Coray T, Mucke L. Ibuprofen, inflammation and Alzheimer disease. Nature Med. 2000; 6; 9:973-974.
99. Bland JS. Functional Medicine Update. 2004 issues.
100. Sobel E, Davinpour Z, Sulkave R, et al. Occupations with exposure to electromagnetic fields: A possible risk factor for Alzheimer's disease. Amer J Epidemiology. 1995; 42; 515-524.
101. Sobel E, Dunn M, Davinpour Z et al. Elevated risk of Alzheimer's disease among workers with likely electromagnetic field exposure. Neurology. 1996; 47:477-1481.
102. Weiner MA. Evidence points to aluminum's link with Alzheimer's disease. TLfDP. 1993; 124:113.
103. McLachlan DRC, Bergeron C, Smith JE, et al. Risk for neuropathologically confirmed Alzheimer's disease and residual aluminum in municipal drinking water employing weighted residential histories. Neurology. 1996; 46:401-405.
104. Crapper McLachlan DR, Dalton AJ, Kruck TP et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet. 1991; 337(8753):1304-1308.
105. Daniels WM, van Rensberg SJ, van Zyl JM et al. Melatonin prevents beta-amyloid induced lipid peroxidation. J Pineal Res. 1998; 24(2); 78-82.
106. Faaender K, Mielke O, Bertsch T, et al. Homocysteine in cerebral macro-angiography and micro-angiography. Lancet. 1999; 353:1586-87.
107. Clarke R, Smith AD, Jobst KA, et al. Folate, vitamin B12, and serum homocysteine levels in confirmed Alzheimer's disease. Arch Neurol. 1998; 55:1449-1455.
108. Dommisse JV. Subtle vitamin-B12 deficiency and psychiatry. Op. cit.
109. Deana R, Vicenti E, Donnella, Deana A. Levels of neurotransmitters in the brains of vitamin-B12-deficient rats. Int Jour Vit Nutr Res. 1977; 47:119-122.
110. Jope RS. Alzheimer's Disease Review. 1996; 1:2-14.
111. Spector R, Cancilla P, Damasio AR. Is idiopathic dementia a regional vitamin-deficiency state? Op. cit.
112. Thieu L. Nghiem, MD, PhD. Interview, 1990.
113. Bland JS. Prev Med Update. May 1995.
114. Earl W. Conroy, DC, ND. Waiora Mara Clinic, Graham Valley RD 1, Motueka, New Zealand. Personal communications, 1992-1995.
115. Rogers SA. Total Wellness. September 2004.
116. Hattersley JG. Lowering cholesterol with Lovastatin: The wrong approach. Jour Orthomolecular Medicine. 1994; 9:54-57.
117. firstname.lastname@example.org Nov. 3, 2004.
118. Graveline, Duane, MD MPH. Lipitor, Thief of Memory. Available at: www.spacedoc.net.
119. Pall, Martin L., PhD. Cobalamin used in chronic fatigue syndrome therapy is a nitric oxide scavenger. Journal of Chronic Fatigue Syndrome 8(2), 2001, pp 39-44. An unidentified supporter has provided further references.
119. Mitsuyama Y, Niegoh H. Serum and cerebrospinal fluid vitamin B12 levels in demented patients with CH3-B12 treatment--preliminary study. Jap Jour Psych Neurology 1988; 42; 1:65-71.
120. WHP Scientific Group on Senile Dementia. Dementias in late life: research & action. Technical Report Series 730, Geneva: World Health Organization, 1986.
121. The Psychiatric manifestations of B12 deficiency. Primary Psychiatry 1996; April: 18, 21.
122. Wallace, DC. Mitochondrial genetics: A paradigm for aging and degenerative diseases. Science 1992; 256: 728-732.
124. Carmel R. Subtle and atypical cobalamin deficiency states. Am J Haematology 1990; 34: 108-114.
125. Bland JS. Prev Med Update. 1993; July.
126. Arnold SE, Kumar A. Reversible dementias. Med Clin NA 1993; 77:215-230.
127. Cunha UGV. An investigation of dementia among elderly outpatients. Acta Psychiatr Scand 1990; 82: 261-263.
128. Crystal HA et al. Serum vitamin B12 levels and incidence in a healthy elderly population. J Amer Geriatrics Soc 1994; 42:933-936.
129. Bland JS. Prev Med Update 1995; Apr.
130. Pirttila T et al Effect of advanced brain atrophy on cognitive functions in non-demented subjects. Acta Neurol Scand 1993; 87: 161-166.
131. Jonathan V. Wright, MD, quoted in Healthtips@agora-inc.com, Mar. 15, 2004.
132. Kuzminski AM, Del Greco EJ, Allen RH, Stabler SP, Lindembaum J., Treatment of cobalamin deficiency with oral cobalamin. Ann Pharmacother 2002; 36: 1268-1272.
133. Jonathan Collin, MD, Lecture 1991.
134. Ferrara A., Arieta S., English WH. Cerebral changes in the course of pernicious anaemia, and their relationship to psychic symptoms. Jour of Neuropathology & Experimental Neurology 1945; 4:217.
135. Burvill PW, Jackson JM, Smith WG. Psychiatric symptoms due to vitamin B12 deficiency without anaemia. Med Jour of Australia 1969. Aug 23: 388-390.
136. Levitt AJ, Joffe RT. Vitamin B12 in psychotic depression. Brit Jour Psychiatry 1988; 153:266-267.
137. Phillips SL, Kahamer KP, An unusual presentation of vitamin B12 deficiency (letter). Amer Jour Psychiatry 1983; 145; 4: 529.
138. Evans DL, Edelsohn GA, Golden RN. Organic psychosis without anaemia or spinal cord symptoms in patients with vitamin B12 deficiency. Amer Jour Psychiatry 1983; 140; 2: 218-221.
139. Elsborg L, Hansen T, Rafaelson OJ. Vitamin B-12 concentrations in psychiatric patients. Acta Psychiatrica Scandinavica 1979; 59: 145-152.
140. Reading CM. Latent pernicious anaemia (letter to the editor). Med Jour Australia 1975; March 29:430-431.
141. Zucker DK, Livingston RL, Narka R, Clayton P. B-12 deficiency and psychiatric disorders: Case report and literature review. Biological Psychiatry 1981; 16; 2: 197-205.
142. Van Tiggelen TJM, Peperkamp JPC. Assessment of vitamin B-12 status in CSF. Amer Jour Psychiatry 1984; 141; 1: 136-137.
143. Levitt AJ, Joffe RT. Vitamin B12 in psychotic depression. Brit Jour Psychiatry 1988; 153: 266-267.
144. Ellis FR, Nasser S. A pilot study of vitamin B-12 in the treatment of tiredness. British Jour Nutrition 1973; April.
145. Story M, Rosen GM. Diet and adolescent behaviour. Psychiatric Annals 1987; 17; 12: 811-817.
146. Greenfield JG, O'Flynn E. Subacute combined degeneration and pernicious anaemia. Lancet 1933; 2: 62-63.
147. Jewesbury ECO. Subacute combined degeneration of the cord and achlorhydric peripheral neuropathies without anaemia. Lancet 1954; 23: 307-312.
148. Dunne, Lavonne. Nutrition Almanac, 3rd ed., NY: McGraw-Hill, 1990.
149. Lipski, Elizabeth, MS, CCN, Digestive Wellness. Keats Publishing Connecticut, Updated 2nd ed., 2000.
150. Dawson DW, Sawers AH, Sharma RK. Malabsorption of protein bound vitamin B12. Brit Med J 1984; 288: 675-678.
151. Suter PM, Golner BB, Golfin BR et al. Reversal of protein-bound vitamin B-12 malabsorption with antibiotics in atrophic gastritis. Gastroenteritis 1991; 101: 1039-1045.
152. Seery JB. Achlorhydria and gastric carcinogenesis. Lancet 1991; 338: 1039-1045.
153. Nilsson-Ehle, Lndahl S, Lindstedct G et al. Low serum vitamin B12 in a population of 70- and 75-year-old subjects. Gastrointestinal causes and hematologic effects. Dig Dis Sci 1989; 34: 716-723.
154. Bland JS. Prev Med Update 1995: Jan.
155. Yao Y et al. Decline of serum cobalamin levels with increasing age among geriatric outpatients. Arch Family Med 1994; 3: 918-922.
156. Saltzman JR et al. Effect of hypochlorhydria due to omeprazole treatment of atrophic gastritis on protein-bound vitamin B12 absorption. Jour Amer Coll Nutr 1994; 13(6): 584-591.
157. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B-12). Ann Intern Med 1994; 120: 311-215.
158. B12 deficiency from drugs. email@example.com 8/18/2004.
159. Mowat C, Carswell A, Wirz A, McKoll KE. Omeprazole and dietary nitrate independently affect levels of vitamin C and nitrite in gastric juice. Gastroenterology 1999; 116; 813-822.
160. Rogers SA. Interview on Bland JS, Prev Med Update 1992: July.
161. Crane MG. Vitamin B12 studies in total vegetarians. J Nutr Med 1994; 4: 419-430.
162. Rogers SA. Letter to Bland JS. Prev Med Update 1995; Apr.
163. Amer J Clin Nutr 1991; 53: 695.
164. Gaby AR. Vegetarian sources of vitamin B12 (Literature review & commentary, brief article.) Townsend Ltr Doc/Patients 2003; May: 32.
165. Calon F, Lim GP, Yang F, Morihara T, Teter B et al. Docosohexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004; 43: 633-645.
166. Wyss-Coray T., Mucke L. Ibuprofen, inflammation and Alzheimer disease. Nature Med. 6; 9: 973-974.
167. Bland JS Functional Medicine Update 2004 issues.
168. Sobel E, Davinpour Z et al, Occupations with exposure to electromagnetic fields: A possible risk factor for Alzheimer's disease. Amer Jour Epidemiology 1995; 42: 515-524.
169. Sobel E, Dunn M, Davinpour Z et al. Elevated risk factor for Alzheimer's disease among workers with likely electromagnetic field exposure. Neurology 1996; 47: 1477-1481.
170. Weiner MA. Evidence points to aluminum's link with Alzheimer' disease. Townsend Ltr for Doctors 1993; #124: 1103.
171. McLachlan DRC, Bergeron C, Smith JE et al. Risk for neuropathologically confirmed Alzheimer's disease and residual aluminum in municipal drinking water employing weighted residential histories. Neurology 1996; 46: 401-405.
172. Crapper McLachlan DR, Dalton AJ, Kruck TP et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991; 337(8753): 1304-1308.
173. Daniels WM, van Rensburg SJ, van Zyl JM et al. Melatonin prevents beta-amyloid induced lipid peroxidation. J Pineal Res 1998; 24(2): 78-82.
174. Faender K, Mielke O, Bertch et al. Homocysteine in cerebral angiopathy and micro-angiopathy. Lancet 1999; 353: 1586-1587.
175. Clarke R, Smith AD, Jobst KA, et al. Folate, vitamin B12, and serum homocysteine levels in confirmed Alzheimer's disease.1998; 55: 1440-1455.
176. Wurtman RJ, Blusctajn J, Maire JC. The autocannabalism of choline containing membrane phospholipids in the pathogenesis of Alzheimer's disease. Pp 17-22 in New Concepts in Alzheimer's Disease. Briley M, Kato A., eds. NY: Plenum Press, 1985.
177. Hoyer S., Nitsch R. Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type. J Neural Transmission 1989; 75: 227-232.
178. Nijst TQ, Wevers RA, Schoondervaldt HC et al. Vitamin B12 and folate concentrations in serum and cerebrospinal fluid of neurological patients with special reference to multiple sclerosis and dementia. J Neurol Neurosurg Psych 1990; 53: 951-94.
179. Regland B, Gottfries CG, Oreland L. Low B12 levels related to high activity of platelet MAO in patients with dementia disorders. Acta Psychiatrica Scandinavica 1988; 53: 951-954.
180. Martins RN, Harper CG, Stokes GB, Masters CLK. Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. J Neurochem 1986; 46: 1042-1053.
181. Halliwell B. Oxidants and the central nervous system: some fundamental questions. Is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke? Acta Neurol Scand 1989; 126: 23-33.
182. McCaddon A, Kelly CL. Alzheimer's disease: A "cobalaminergic" hypothesis. Med Hypotheses 39: 161-165.
183. Reading CM. X-linked dominant manic-depressive illness. Op. cit.
184. Reading CM. Latent pernicious anaemia: A preliminary report. Med Jour Australia 1975(Jan.25); 1: 91-94.
185. Klein P. Nature 2003; 423:435-439.
186. Wright JV. Lithium, Part 2; other effects. Townsend Ltr Doc/Patients 2004; Apr: 59-61.
187. LITHIUM from Sherry A. Rogers, MD, TOTAL WELLNESS, 2003.
188. Fiero AA. Natural low-dose lithium supplementation in manic-depressive disease. Nutrition Perspectives 1988 (Jan.): pp 10-11.
189. Kleinjen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacology 1992; 34: 352-358.
190. Human Psychopharm 1994; 9: 352-368.
191. Oken BS. The efficacy of ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurology 1998(Nov); 55: 1409-1415.
192. Jour Amer Med Assoc 1997; 278: 1327-1332.
193. EurekAlert 2004 (Aug 19).
194. Little CS, Hammond CJ, Macintyre A, Balin BJ, Appelt DM. Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiology of Aging 2004; 25: 419-429. firstname.lastname@example.org
195. Economist (author's name is never shown) 2004 (Mar. 20): 37-38.
196. Hattersley JG. Infantile heart attack: A cause of SIDS? Jour Applied Nutr 2002; 52; 3&4: 69-78.
197. Nigel Plummer, PhD, Lecture to Neural therapy seminar in Seattle. Dec. 1, 2001.
198. "Effect of Helicobacter pylori eradication on High density lipoprotein cholesterol," Amer Jour Cardiology, 2004 (Jan. 15); 93(2): cardiosource.com.
199. "Last week it was cancer. This week it's heart disease." Brian Hoyle. National Rev of Medicine, 2004 (Mar 30); 1(6): nationalreviewofmedicine.com
200. Marysiak-Budnik T, Heyman M. Food allergy and Helicobacter pylori infection. Jour Pediatric Gastroenteroloy & Nutrition 2002; 34; 1: 5-12.
201. Mechanism of focal infection. J Amer Dental Assoc. 1951(June); 42: 619-633.
202. Fischer Martin H, MD. Death by Dentistry, Baltimore: Charles C. Thomas, 1940.
203. Meinig George E, DDS. Root Canal cover-up Exposed! Ojai, CA: Bion Publ., 1993.
204. Kroes L, Lep PW, Relman DA. Bacterial diversity within the human subgingival crevice. Proc Nat Acad Sci USA 1999 (Dec 7); 96; 25: 14547-14552.
206. (1) Details on Cobalamin. Cobalamin for Soil & Animal Health, by Jerry Brunetti. Acres-USA, Sept. 2005: pp 11, 33; reprinted from Weston A. Price Foundation, PMB 106-380, 4200 Wisconsin Ave NW, Washington, DC 20016. The paper is essential to understanding of our material. A few copies are available from me on request.
(2) Background on John Dommissee, MD. Emphasize the first syllable, viz. DOMmissee. He is of Dutch-Africaans origin, earned his first MD degree at the very advanced University of Johannesburg, South Africa and flies down there occasionally. He earned a second, nutritionally oriented MD degree at University of Toronto in 1967.
Dr Dommisse works out of an office at 1840 E. River Road, Suite 210, in Tucson, AZ 85718. (520) 577-1940. john@johndommisseMD.com He specializes in treatment of subclinical hypothyroid conditions, and maintains contact with his patients worldwide by email. He told me his treatment of that condition is "the best in the world."
Medical societies have tried for the past eight, and especially the last four years to deprive Dr Dommissee of his license to practice medicine--presumably because his successful high-dose B12 therapy deprives many physicians of ongoing patients' visits and sales of medications.